Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Steam recall expanded

This article was originally published in The Tan Sheet

Executive Summary

Nutracoastal Trading expands the voluntary recall of Steam dietary supplements to include lot 90260 because it includes undeclared tadalafil, the active ingredient in the prescription erectile dysfunction drug Cialis. The Freeport, N.Y., company first recalled Steam July 28 after FDA found it included sulfoaildenafil, an anolog of sildenafil, the active ingredient in Viagra (1"The Tan Sheet" Aug. 3, 2009, In Brief)

You may also be interested in...



Double trouble for Nutracoastal

The Freeport, N.Y., company voluntarily recalls two products it markets nationwide as dietary supplements after FDA finds they contain active pharmaceutical ingredients. The Steam supplement was found to have sulfoaildenafil, an analog of the erectile dysfunction drug sildenafil, Nutracoastal Trading and FDA announced July 28. The S-DROL product was found to contain the undeclared steroid desoxymethyltestosterone. FDA said Nutracoastal's steroid-containing tablets are similar to those involved in the agency's warning to American Cellular Labs, but would not confirm whether Nutracoastal's products were linked to any adverse event reports (see story p. 8)

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel